Pooled Nucleic Acid Testing to Identify Antiretroviral Treatment Failure During HIV Infection

Background:Pooling strategies have been used to reduce the costs of polymerase chain reaction-based screening for acute HIV infection in populations in which the prevalence of acute infection is low (less than 1%). Only limited research has been done for conditions in which the prevalence of screening positivity is higher (greater than 1%). Methods and Results:We present data on a variety of pooling strategies that incorporate the use of polymerase chain reaction-based quantitative measures to monitor for virologic failure among HIV-infected patients receiving antiretroviral therapy. For a prevalence of virologic failure between 1% and 25%, we demonstrate relative efficiency and accuracy of various strategies. These results could be used to choose the best strategy based on the requirements of individual laboratory and clinical settings such as required turnaround time of results and availability of resources. Conclusions:Virologic monitoring during antiretroviral therapy is not currently being performed in many resource-constrained settings largely because of costs. The presented pooling strategies may be used to significantly reduce the cost compared with individual testing, make such monitoring feasible, and limit the development and transmission of HIV drug resistance in resource-constrained settings. They may also be used to design efficient pooling strategies for other settings with quantitative screening measures.

[1]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[2]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[3]  Victoria A Johnson,et al.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Hae-Young Kim,et al.  Comparison of Group Testing Algorithms for Case Identification in the Presence of Test Error , 2007, Biometrics.

[5]  P. Harrigan,et al.  Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays , 1998, Journal of Clinical Microbiology.

[6]  S. Hammer,et al.  The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. , 1999, AIDS.

[7]  S. Glynn,et al.  A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors , 2005, Transfusion.

[8]  Inyoung Kim,et al.  Bayesian Methods for Predicting Interacting Protein Pairs Using Domain Information , 2007, Biometrics.

[9]  R. Schooley,et al.  Running with scissors: using antiretroviral therapy without monitoring viral load. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[11]  R. Haubrich,et al.  A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Gaudino,et al.  Sensitivity and specificity of pooled versus individual sera in a human immunodeficiency virus antibody prevalence study , 1989, Journal of clinical microbiology.

[13]  T. Quinn,et al.  Successful use of pooled sera to determine HIV-1 seroprevalence in Zaire with development of cost-efficiency models. , 1990, AIDS.

[14]  L. Jagodzinski,et al.  Use of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 To Assess the Performance of Viral RNA Quantitation Tests , 2000, Journal of Clinical Microbiology.

[15]  L. Wolf,et al.  Frequent detection of acute HIV infection in pregnant women , 2007, AIDS.

[16]  D. Richman,et al.  Predictors of Self‐Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral Regimens , 2000, Journal of acquired immune deficiency syndromes.

[17]  B. Yip,et al.  Performance of Immunologic Responses in Predicting Viral Load Suppression: Implications for Monitoring Patients in Resource-Limited Settings , 2006, Journal of acquired immune deficiency syndromes.

[18]  J. Rodriquez,et al.  Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. , 2005, The Journal of infection.

[19]  Cathy A Petti,et al.  Laboratory medicine in Africa: a barrier to effective health care. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R Brookmeyer,et al.  Analysis of Multistage Pooling Studies of Biological Specimens for Estimating Disease Incidence and Prevalence , 1999, Biometrics.

[21]  R Brookmeyer,et al.  Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence , 2000, AIDS.

[22]  Tx Station.  Stata Statistical Software: Release 7. , 2001 .

[23]  B. Strom,et al.  Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy , 2006, AIDS.

[24]  Cheryl Jennings,et al.  HIV-1 Viral Load Assays for Resource-Limited Settings , 2006, PLoS medicine.

[25]  Marcello Pagano,et al.  On the informativeness and accuracy of pooled testing in estimating prevalence of a rare disease: Application to HIV screening , 1995 .

[26]  D Johnson,et al.  The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.

[27]  J. Schapiro,et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.

[28]  P. Harrigan,et al.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.

[29]  B. Larder,et al.  Mutational Patterns in the HIV Genome and Cross-Resistance following Nucleoside and Nucleotide Analogue Drug Exposure , 2000, Antiviral therapy.

[30]  Christopher D Pilcher,et al.  Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. , 2002, JAMA.

[31]  M. Hughes,et al.  Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.

[32]  Deenan Pillay,et al.  Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model , 2008, The Lancet.

[33]  William C Miller,et al.  Detection of acute infections during HIV testing in North Carolina. , 2005, The New England journal of medicine.

[34]  N. Ford,et al.  HIV viral load monitoring in resource-limited regions: optional or necessary? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  I. Sanne,et al.  Cost-Effectiveness of Alternative Strategies for Initiating and Monitoring Highly Active Antiretroviral Therapy in the Developing World , 2007, Journal of acquired immune deficiency syndromes.

[36]  Joseph L. Gastwirth,et al.  Dual group screening , 2000 .

[37]  H. Günthard,et al.  Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice , 2002, Antiviral therapy.

[38]  J. Nachega,et al.  Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy , 2008, PLoS medicine.

[39]  S Zeger,et al.  Evaluation of human immunodeficiency virus seroprevalence in population surveys using pooled sera , 1989, Journal of clinical microbiology.

[40]  Joseph L. Gastwirth,et al.  Estimation of the prevalence of a rare disease, preserving the anonymity of the subjects by group testing: application to estimating the prevalence of aids antibodies in blood donors , 1989 .

[41]  P. Harrigan,et al.  Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. , 1999, The Journal of infectious diseases.

[42]  Joseph L. Gastwirth,et al.  Group Testing for Sensitive Characteristics: Extension to Higher Prevalence Levels , 1994 .

[43]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[44]  A. Sterrett.  On the Detection of Defective Members of Large Populations , 1957 .

[45]  Christopher D. Pilcher,et al.  Optimizing Screening for Acute Human Immunodeficiency Virus Infection with Pooled Nucleic Acid Amplification Tests , 2008, Journal of Clinical Microbiology.